麻豆果冻传媒影音

People with any evidence of with diet and lifestyle changes had a 40% lower rate of cardiovascular disease and a 33% lower rate of chronic kidney disease versus those without remission, according to additional findings from the Look AHEAD study. (Diabetologia)

Among kids with overweight or obesity, the risk for was 72-fold higher in those with baseline HbA1c levels of 6.3% to 6.4% compared with those with a baseline level under 5.5%. (JAMA Network Open)

JDRF, formerly known as the Juvenile Diabetes Research Foundation, awarded $9 million to fund a pivotal clinical trial testing the dual (Inpefa) in the treatment of kidney complications in patients with type 1 diabetes. The drug was rejected by the FDA for type 1 diabetes back in 2019 but nabbed an approval last year for a heart failure indication.

A Utah interventional endocrinologist performed the first in the U.S. earlier this month, Baird Medical Devices announced.

may be protective against type 2 diabetes among lactase non-persistent individuals, possibly driven by involvement of gut microbiota and blood metabolites. (Nature Metabolism)

People with obesity experiencing the lowest levels of had 36% and 9% lower mortality risks, respectively, compared with those experiencing the highest levels. (JAMA Network Open)

Price check for in 2024: the list price for semaglutide (Ozempic) is up 3.5%, to roughly $970 for a month's supply, while the price for tirzepatide (Mounjaro) jumped 4.5%, to about $1,070. (Becker's Hospital Review)

Roughly 56% of patients remained about the same weight or continued to lose weight (Ozempic, Wegovy) or liraglutide (Saxenda), according to an Epic Research study.

Ohio may become the second state to in adults. Meanwhile, state lawmakers in banning health professionals from providing gender-affirming care to minors. (AP)

An reduced blood sugar levels without causing hypoglycemia in a baboon study. (Nature Nanotechnology)

Stress in adolescence was linked with in young adulthood. (Journal of the American Heart Association)

The will consider wider use of the weight-loss formulation of semaglutide to reduce the risk of strokes and heart attacks. (Reuters)

Comment